Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 531-540 of 2766 for cancer

Edit search filters
  1. A Study Using the New TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients with Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

    Scottsdale/Phoenix, AZ

  2. A Study To Evaluate The Safety Of Lasofoxifene In Combination With Abemaciclib In Advanced Or Metastatic ER+/HER2− Breast Cancer With ESR1 Mutation

    Jacksonville, FL, Rochester, MN

  3. A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  4. Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Rochester, MN

  5. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  6. A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Rochester, MN

  7. Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

    Rochester, MN

  8. Bemarituzumab Or Placebo Plus Chemotherapy In Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. Pembrolizumab Plus Epacadostat Alone or With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-02/ECHO-306)

    Rochester, MN

  10. A Study to Test Nivolumab with Usual Chemotherapy Treatment or Usual Chemotherapy Treatment Alone to Treat Recurrent or Metastatic Nasopharyngeal Cancer

    Jacksonville, FL

.

Mayo Clinic Footer